Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
57 hedge funds and large institutions have $130M invested in Osiris Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 12 closing their positions.
186% more capital invested
Capital invested by funds: $45.4M → $130M (+$84.3M)
171% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 7
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
24% more funds holding
Funds holding: 46 → 57 (+11)
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $963K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$20M |
| 2 |
Renaissance Technologies
New York
|
+$5.58M |
| 3 |
Millennium Management
New York
|
+$4.94M |
| 4 |
Goldman Sachs
New York
|
+$4.22M |
| 5 |
WIC
Water Island Capital
New York
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cloverdale Capital Management
Dallas,
Texas
|
-$4.42M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$1.76M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.19M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$927K |
| 5 |
CG
Caprock Group
Boise,
Idaho
|
-$473K |
OSIR Hedge Fund Activity: Q1 2019 in Review
57 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2019, worth a combined $130M — up 186% from $45.4M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new OSIR positions and 12 closed out — a net gain of 13 holders — while 19 added to existing stakes and 7 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $20M. The largest seller was Cloverdale Capital Management, cutting an estimated $4.42M.
- 57 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2019, up from 46 in Q4 2018.
- Funds reported $130M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2019, up 186% quarter-over-quarter.
- 25 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2019 and 12 closed out, a net change of +13 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2019 was Alpine Associates Management, an estimated $20M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2019 was Cloverdale Capital Management, an estimated $4.42M sold.
Based on aggregated 13F filings for Q1 2019.